November 28, 2016 / 9:16 PM / 9 months ago

BRIEF-Galapagos NV reports initiation of a phase 1 study with GLPG2737

1 Min Read

Nov 28 (Reuters) - Galapagos NV

* Galapagos NV says reports initiation of a phase 1 study in healthy volunteers with GLPG2737, a novel C2 corrector drug for cystic fibrosis

* Galapagos NV says topline results from this phase 1 study with GLPG2737 are expected in Q2 of 2017

* Galapagos NV says initiation of phase 1 study triggers a $10 million milestone payment from AbbVie Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below